IKBKB and neoplasm: Inspired by this view, Wang et al. used M2-targeted/pH-responsive lipid NPs encapsulating IMD-0354 (a IKKβ inhibitor) for selectively triggering M2-type TAMs repolarization through the inhibition of IKKβ, synergized with the chemotherapy of lipid NPs-formulated sorafenib (SF) for remodeling tumor immunosuppression and enhancing therapeutic potency (Figure 11C, D) 42.